Regeneron Pharmaceuticals Aktie

Regeneron Pharmaceuticals für 0 Euro bei ZERO ordern (zzgl. Spreads)

WKN: 881535 / ISIN: US75886F1075

<
News + Analysen
News + Adhoc
Analysen
Kursziele
>
<
Unternehmen
Termine
Profil
>
<
zugeh. Wertpapiere
Zertifikate
Optionsscheine
Knock-Outs
>
<
Aktion
Portfolio
Watchlist
>
29.04.2026 12:53:55

Cognizant Updates FY26 Guidance

(RTTNews) - Cognizant (CTSH) said its 2026 adjusted operating margin guidance is increased to 16.0% to 16.2%, year-over-year expansion of 20 to 40 basis points compared to prior guidance of 10 to 30 basis points of expansion. Constant currency revenue growth guidance is unchanged at 4.0% to 6.5%. Full-year 2026 adjusted EPS is expected to be in the range of $5.63 to $5.77, growth of 7% to 9%. The company expects second quarter revenue to be $5.45 to $5.52 billion, growth of 3.8% to 5.3%, or 3.2% to 4.7% in constant currency.

First quarter net income was $662 million compared to $663 million, prior year. EPS was $1.39, increased 3.7% year-over-year. Adjusted EPS was $1.40 increased 13.8%. Adjusted Operating Margin was 15.6%, increased 10 basis points year-over-year. Revenue was $5.4 billion, up 5.8% from last year, or 3.9% in constant currency.

In pre-market trading on NasdaqGS, Cognizant shares are down 4.75 percent to $52.50.

For more earnings news, earnings calendar, and earnings for stocks, visit rttnews.com.

Analysen zu Regeneron Pharmaceuticals Inc.

mehr Analysen
Eintrag hinzufügen
Hinweis: Sie möchten dieses Wertpapier günstig handeln? Sparen Sie sich unnötige Gebühren! Bei finanzen.net Brokerage handeln Sie Ihre Wertpapiere für nur 5 Euro Orderprovision* pro Trade? Hier informieren!
Es ist ein Fehler aufgetreten!

Aktien in diesem Artikel

Regeneron Pharmaceuticals Inc. 599,30 2,04% Regeneron Pharmaceuticals Inc.